Healthcare industry

The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.

HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

TWYCE GmbH - 10/07/2024

Better immune response against prostate cancer thanks to new bispecific antibodies

TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.